Introduction
Primary sclerosing cholangitis (PSC) has a highly variable disease course and reliable prognostic biomarkers are lacking. Current markers mainly reflect fibrosis burden and may not capture ongoing extracellular matrix (ECM) remodeling.
Aims & Methods
The aim of this study was to evaluate the prognostic value of a wide panel of ECM remodeling biomarkers for transplant-free survival in PSC. Biobanked serum samples were collected from PSC patients at a single tertiary non-transplant centre in the Netherlands. The primary endpoint was defined as all-cause mortality or liver transplantation; a secondary endpoint was all-cause mortality or liver transplantation due to end-stage liver disease only. ECM remodeling biomarkers reflecting collagen synthesis and assembly (PRO-C3, PRO-C5, PRO-C6, PRO-C16, TSP-2), collagen degradation (C3M, C4A3-HNE) and neutrophil activation (CPa9-HNE) were measured, alongside Enhanced Liver Fibrosis (ELF) score and its individual components (hyaluronic acid (HA), amino-terminal propeptide of type III procollagen (P3NP), tissue inhibitor of metalloproteinases 1 (TIMP-1)). Marker levels were log-transformed prior to analyses. Prognostic value was assessed using Cox proportional hazards models adjusted for sex and for age at sample collection. Odds ratios (OR) for transplant-free survival were calculated comparing the lowest (T1) and the highest tertile (T3) of each marker. Discriminative ability was assessed using time-dependent area under the curve (AUC) analyses at 5 years. Alkaline phosphatase (ALP) was included as a reference standard laboratory marker. Sensitivity analyses were performed excluding patients with small-duct disease and patients with events within 3 months of sample collection.
Results
A total of 249 PSC patients were included (64% male, 88% large-duct, 68% inflammatory bowel disease (IBD), 6% features of autoimmune hepatitis (AIH)). Median age at baseline was 43 years (IQR 29-55), with a median PSC duration of 5.0 years (IQR 2.3-12.3) and a median follow-up time of 5.2 years (IQR 3.5-13.7). During follow-up, 74 patients (30%) reached the primary endpoint and 64 (26%) reached the secondary endpoint. Several markers were significantly associated with transplant-free survival, with the strongest associations observed for PRO-C3, TSP-2, and ELF and its components (HA, P3NP and TIMP-1) (Table 1). These markers also showed the highest discriminative ability, with 5-year AUC values ranging from 0.75 to 0.80. TSP-2 showed the highest OR for the highest versus lowest tertile (OR 11.97, 95% CI 5.20-31.36). Results were consistent for the secondary endpoint and in sensitivity analyses.
Table 1. Prognostic performance of ECM remodeling markers in PSC
Marker
| HR (95% CI)*
| p-value
| OR T3 vs T1 (95% CI)
| 5 yr AUC (95% CI)
|
|---|
Collagen formation and assembly markers - PRO-C3 (ng/mL) - PRO-C3 (ELECSYS) (ng/mL) - PRO-C6 (ng/mL) - PRO-C16-HP (ng/mL) - PRO-C5-HP (ng/mL) - TSP-2 (ng/mL) | 3.84 (2.64-5.59) 2.90 (1.85-4.56) 3.92 (1.96-7.84) 0.98 (0.56-1.72) 0.90 (0.44-1.82) 3.33 (2.36-4.71) | <0.001 <0.001 <0.001 0.945 0.766 <0.001 | 6.09 (2.91-13.63) 2.69 (1.37-5.46) 1.88 (0.97-3.72) 0.37 (0.19-0.71) 0.73 (0.38-1.38) 11.97 (5.20-31.36)
| 0.76 (0.67-0.84) 0.67 (0.58-0.77) 0.71 (0.62-0.80) 0.55 (0.45-0.66) 0.52 (0.41-0.63) 0.78 (0.70-0.86)
|
Collagen degradation - C3M (ng/mL) - C3M-HP (ng/mL) - C4A3-HNE (ng/mL)
| 3.66 (1.54-8.70) 2.99 (1.13-7.91) 1.14 (0.63-2.04)
| 0.003 0.028 0.673
| 2.63 (1.35-5.28) 2.01 (1.03–4.01) 0.84 (0.43-1.64)
| 0.64 (0.54-0.75) 0.60 (0.50-0.70) 0.49 (0.38-0.59)
|
Neutrophil activation - CPa9-HNE (unit/mL)
| 1.53 (0.85-2.76)
| 0.160 | 0.69 (0.36-1.31)
| 0.66 (0.56-0.76)
|
ELF (incl. individual components) - ELF score - HA (ng/mL) - P3NP (ng/mL) - TIMP-1 (ng/mL) | 1.92 (1.62-2.29) 2.35 (1.86-2.96) 3.11 (2.12-4.57) 5.79 (3.20-10.5) | <0.001 <0.001 <0.001 <0.001 | 6.71 (3.21-15.02) 6.07 (2.99-13.03) 5.05 (2.51-10.64) 4.58 (2.28-9.66) | 0.80 (0.71-0.89) 0.78 (0.70-0.87) 0.75 (0.65-0.84) 0.78 (0.69-0.87)
|
Reference marker ALP (U/L) ** |
2.67 (1.79-3.98)
|
<0.001
|
6.16 (2.68-15.65)
|
0.72 (0.62-0.82)
|
*HR per unit increase in natural log-transformed marker value (ELF on raw scale), adjusted for age at sample collection and sex.
**ALP analyses based on 210 patients (84%) due to missing values.
Conclusion
ECM remodeling biomarkers, particularly PRO-C3, TSP-2 and ELF (including its individual components), are strongly associated with transplant-free survival in PSC. These findings support further research on ECM remodeling biomarkers for risk stratification in PSC and their potential as surrogate endpoints in clinical trials.
Disclosure
This study was funded by Takeda Pharmaceuticals. AZ and DJL are employees at Nordic Bioscience. DJL holds stocks in Nordic Bioscience. JCC, ZD, XH, JX and PT are employees of Takeda Pharmaceuticals and hold stocks in Takeda. CP received research grants from Perspectum, NGM, Takeda, and Dr. Falk Pharma, and advisory fees from Chemomab. The remaining authors declare no conflicts of interest.